• Molecular NameEphedrine
  • SynonymNA
  • Weight165.236
  • Drugbank_IDDB01364
  • ACS_NO50906-05-3
  • Show 3D model
  • LogP (experiment)0.93
  • LogP (predicted, AB/LogP v2.0)1.05
  • pka9.6
  • LogD (pH=7, predicted)-1.27
  • Solubility (experiment)56 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.78
  • LogSw (predicted, AB/LogsW2.0)80.66
  • Sw (mg/ml) (predicted, ACD/Labs)38.66
  • No.of HBond Donors2
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds3
  • TPSA32.26
  • StatusFDA approved
  • Administrationoral, IV, IM, SC
  • PharmacologyA sympathomimetic amine commonly used as a stimulant, appetite suppressant, concentration aid, decongestant, and to treat hypotension associated with anaesthesia.
  • Absorption_valueN/A
  • Absorption (description)Readily absorbed after oral or percutaneous administration.
  • Caco_2N/A
  • Bioavailability85.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolised by N-demethylation to norephedrine (phenylpropanolamine) and by oxidative deamination followed by conjugation. Accumulates in the liver, lungs, kidneys, spleen, and brain.
  • Half life3~6 h but may be increased when the urine is alkaline and decreased when it is acid.
  • ExcretionAbout 90% of a dose is excreted in the urine in 24 h, with about 55 to 75% of the dose as unchanged drug, 8 to 20% as norephedrine, and 4 to 13% as deaminated metabolites such as benzoic acid, hippuric acid, and 1-phenylpropane-1,2-diol. In acidic urine, excretion of unchanged drug is increased slightly, whereas, in alkaline urine, about 20 to 35% of the dose is excreted unchanged and the proportion of norephedrine is increased. Ephedrine is a metabolite of methylephedrine.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe estimated minimum lethal dose in children up to 2 years of age is 200 mg and for adults 2 g but fatalities are rare. Single doses of up to 400 mg have been given without causing serious toxic effects.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A